NEW DELHI: New Delhi, January 27: A Delhi-based pharmaceutical company has launched a new tricycle drug to treat severe cases of canine trichotillomania (CTM) and other disorders that affect the dog’s ability to walk.

The company, Eyerf Dog, is testing the drug in four breeds, including the German shepherd, Bernese Mountain dog, Poodle, Dachshund and Labrador Retriever.

Its chief executive, Manish Dutta, said the drug is a good option for the veterinary industry and will be available for a limited time in November.

He said the first batch of 10,000 units will be delivered to veterinary hospitals across the country in November and December.

Dutta said the company has been researching and developing the drug for more than five years and has submitted its patents in India.

“It’s not a cheap drug but it’s not expensive either.

It costs less than $200 for a 10,00 unit supply,” he said.

Eyerf says it has developed a specialised version of the drug, called EyerFo, which was developed specifically for dogs.

EyerFos can be given in a tablet, which is inserted into the dog or injected in the neck, Dutts said.

He said it was the first time the drug had been used in the veterinary field.

EsterFo is a special formulation of the EyerMorphine, which Eyer is selling in India, he said, adding that Eyer was developing the EsterFos drug specifically for the canine market.